LOS ANGELES--(BUSINESS WIRE)--Advanced Cell Technology, Inc. (OTCBB: ACTC) today announced the promotion of Dr. Robert Lanza, M.D., to the position of Chief Scientific Officer. Dr. Lanza joined Advanced Cell Technology in 1999 and has developed and managed several of the company’s human embryonic stem cell (hESC) research programs including, but not limited to, the Retinal Pigment Epithelial (RPE) Cell Program, the Hemangioblast (HG) Cell Program and the Somatic Cell Nuclear Transfer (SCNT) research. Dr. Lanza will continue to work closely with Dr. Pedro Huertas, M.D., Ph.D., ACT’s Chief Development Officer, to drive these hESC therapies to the clinical development stage. The company expects to file INDs for its RPE and HG Programs in 2008.
